Vitexin, with a purity >99.9%, was obtained from Xi'an Haoxuan Biotechnology Co. Ltd., (Xi'an, China). The P38 MAPK inhibitor,
SB203580, was purchased from Selleck Chemicals (Houston, TX, USA).
RPMI-1640 medium and
fetal bovine serum (FBS) were purchased from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA).
LPS was purchased from Sigma-Aldrich; Merck Millipore Darmstadt, (Germany). Rabbit polyclonal antibodies against
HMGB1 (Rabbit IgG, cat. no. 6893, 1:1,000), Bcl2 (Rabbit IgG, cat. no. 2876, 1:1,000), cleaved caspase-3 (Rabbit IgG, cat. no. 9664, 1:1,000), P38 (Rabbit IgG, cat. no. 14451, 1:1000), phosphorylated (p-)P38 (Rabbit IgG, cat. no. 4092, 1:1,000) and
β-actin (Rabbit IgG, cat. no. 4970, 1:1,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The streptavidin-peroxidase (SP) and 3,3′-diaminobenzidine kits were purchased from Beijing Zhongshan Golden Bridge Biotechnology; OriGene Technologies, Inc. (Rockville, MD, USA). The primers (P38, F:GCC TCA CCG CCT CAG TAT , R:GCA GTC TTC TCA TTC CCT TG;
β-actin, F:TTT TGT GCC TTG ATA GTT CG, R:GGA GTC CTT CTG ACC CAT AC-3) for P38 (Mapk14) and
β-actin were synthetized by Sangon Biotech Co., Ltd. (Shanghai, China).
HMGB1 and the
TNF-α enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems (Minneapolis, MN, USA).
Wang F., Yin J., Ma Y., Jiang H, & Li Y. (2017). Vitexin alleviates lipopolysaccharide-induced islet cell injury by inhibiting HMGB1 release. Molecular Medicine Reports, 15(3), 1079-1086.